title: Current status of chemically synthesized inhibitors of Ebola virus.
abstract: The current Ebola virus outbreak is unprecedented in its scope and international impact. Given that there are currently no approved antivirals to treat Ebola virus, there is urgency to conduct more rapid development and evaluation of Ebola antivirals. Recently, the World Health Organization identified a number of antivirals as high priority to include AVI-6002 (AVI-7537 and AVI-7539), BCX4430, brincidofovir, favipiravir, and TKM-100802. This review describes these chemically synthesized inhibitors of Ebola virus, relevant patent development and gives an update on their current status.
authors: Division of Medicine, US Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Frederick, MD 21702, USA. anthony.p.cardile.mil@mail.mil.
authors: Anthony P
authors: AP
authors: Cardile
authors: Douglas L
authors: DL
authors: Mayers
authors: Sina
authors: S
authors: Bavari
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000241:Adenosine / Q000031:analogs & derivatives; D000577:Amides / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D003596:Cytosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D055808:Drug Discovery; D029043:Ebolavirus; D019142:Hemorrhagic Fever, Ebola / Q000188:drug therapy*; D006801:Humans; D063065:Organophosphonates / Q000627:therapeutic use; D010330:Patents as Topic; D011684:Purine Nucleosides / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D011759:Pyrrolidines
chemical_list: D000577:Amides; D000998:Antiviral Agents; D063065:Organophosphonates; D011684:Purine Nucleosides; D011719:Pyrazines; D011759:Pyrrolidines; C525733:brincidofovir; D003596:Cytosine; C462182:favipiravir; D000225:Adenine; D000241:Adenosine; C517546:galidesivir